Comparative chemical and biological studies of four prototype phosphoraziridine antineoplastic agents.

[1]  W. Rose,et al.  Synthesis of new nucleoside phosphoraziridines as potential site-directed antineoplastic agents. , 1990, Journal of medicinal chemistry.

[2]  T. Bardos,et al.  Synthesis and testing of quinone-based bis(2,2-dimethyl-1-aziridinyl)phosphinyl carbamates as radiation-potentiating antitumor agents. , 1988, Journal of Medicinal Chemistry.

[3]  M. Perlman,et al.  Synthesis, molecular symmetry, and chemical reactivity of C-aryl-substituted phosphoraziridines , 1988 .

[4]  W. Rose,et al.  Synthesis and properties of bis(2,2-dimethylaziridinyl)phosphinic amides: a series of new antineoplastic agents. , 1985, Journal of medicinal chemistry.

[5]  G. Wampler,et al.  A pilot study with ethyl bis (2,2-dimethyl-1-aziridinyl) phosphinate (AB-163) and radiation therapy. , 1982, International journal of radiation oncology, biology, physics.

[6]  T. Bardos,et al.  Synthesis of 5'-thymidinyl bis(1-aziridinyl)phosphinates as antineoplastic agents. , 1981, Journal of Medicinal Chemistry.

[7]  H. Kann,et al.  Effects of structure and chemical activity on the ability of nitrosoureas to inhibit DNA repair. , 1980, Cancer research.

[8]  G. Wampler,et al.  Radiation potentiating effect of ethyl bis(2,2-dimethyl-1-aziridinyl) phosphinate (AB-163). , 1979, International journal of radiation oncology, biology, physics.

[9]  J. A. Dunn,et al.  Chemical mechanism of the radiation potentiating effects of 2,2-dimethylaziridine-type antitumor agents. , 1979, International journal of radiation oncology, biology, physics.

[10]  I. Wodinsky,et al.  Combined therapy with an aziridine derivative NSC 200724 (AB182) and radiation on an experimental leukemia. , 1979, International Journal of Radiation Oncology, Biology, Physics.

[11]  K W Kohn,et al.  DNA-protein cross-linking and DNA interstrand cross-linking by haloethylnitrosoureas in L1210 cells. , 1978, Cancer research.

[12]  K. Kohn,et al.  Fractionation of DNA from mammalian cells by alkaline elution. , 1976, Biochemistry.

[13]  D. Lalka,et al.  Cyclophosphamide, 2,2-dimethylaziridines and other alkylating agents as inhibitors of serum cholinesterase. , 1975, Biochemical pharmacology.

[14]  G. Wampler,et al.  Synthfsis of bis(aziridinyl)phosphinyl-N-hydroxyurethane derivatives as antineoplastic agents. , 1975, Journal of medicinal chemistry.

[15]  A. Sartorelli,et al.  Antineoplastic and Immunosuppressive Agents , 1975, Handbuch der experimentellen Pharmakologie / Handbook of Experimental Pharmacology.

[16]  W. Ross.  Rational Design of Alkylating Agents , 1974 .

[17]  D. Lalka,et al.  Reactions of 2,2-dimethylaziridine-type alkylating agents in biological systems. I. Colorimetric estimation and stability in physiological media. , 1973, Journal of pharmaceutical sciences.

[18]  C. Ambrus,et al.  Combination of chemotherapy with dual antagonists and radiotherapy in the treatment of neoplastic disease , 1971, Journal of surgical oncology.

[19]  T. Bardos,et al.  Mechanisms of reactions of ring-substituted bis(1-aziridinyl)phosphinyl urethan antineoplastic agents. , 1970, Journal of pharmaceutical sciences.

[20]  A. Munson,et al.  Synthesis and chemotherapeutic effects of ethyl bis-(2,2-dimethyl)-ethylenamido phosphate. A preliminary report. , 1967, Journal of pharmaceutical sciences.

[21]  D. Triggle,et al.  A STUDY OF COMPARATIVE CHEMICAL AND BIOLOGICAL ACTIVITIES OF ALKYLATING AGENTS. , 1965, Journal of medicinal chemistry.

[22]  T. Bardos,et al.  Synthesis of Potential Dual Antagonists III , 1965 .

[23]  T. Bardos,et al.  SYNTHESIS OF POTENTIAL DUAL ANTAGONISTS. 3. RING-SUBSTITUTED ETHYL (BIS(1-AZIRIDINYL)PHOSPHINYL)CARBAMATES. , 1965, Journal of pharmaceutical sciences.

[24]  J. Webster,et al.  Combined use of AB‐132 (Meturedepa, Turloc) and X irradiation in the management of advanced bronchogenic carcinoma , 1964, Cancer.

[25]  W. Regelson,et al.  THE EFFECT OF RADIATION ON SPLENOMEGALY INDUCED BY THE FRIEND LEUKEMIA VIRUS AND ITS MODIFICATION BY ETHY-N-BIS(2,2-DIMETHYL-ETHYLAMIDINOPHOSPHORO)-CARBAMATE (AB-132), ACTINOMYCIN D, AND AET. , 1964, Radiation research.

[26]  H. Petering,et al.  COLORIMETRIC METHOD FOR DETERMINATION OF URACIL MUSTARD AND RELATED ALKYLATING AGENTS. , 1963, Journal of pharmaceutical sciences.

[27]  T. Bardos.  Consideration of chemical reaction mechanisms in relationship to the biological action of "dual antagonists". , 1962, Biochemical pharmacology.

[28]  J. Sokal,et al.  Use of AB‐103 (a “dual antagonist”) in the treatment of bronchogenic carcinoma , 1961, Cancer.

[29]  O. M. Friedman,et al.  Colorimetric Estimation of Nitrogen Mustards in Aqueous Media. Hydrolytic Behavior of Bis-(β-chloroethyl)amine, nor HN2 , 1961 .

[30]  A. Segaloff,et al.  Clinical Experience with AB‐100: Results of Therapy in 123 Patients , 1961, Southern medical journal.

[31]  A. Segaloff,et al.  ‘Dual Antagonists’; Alkyl N-(bis-(ethylenimido)phosphoro)-carbamates; a New Series of Anti-Tumour Agents , 1959, Nature.

[32]  C. Price.  FUNDAMENTAL MECHANISMS OF ALKYLATION , 1958, Annals of the New York Academy of Sciences.

[33]  R. Rosenthal,et al.  Use of γ-(4-Nitrobenzyl)pyridine as Analytical Reagent for Ethylenimines and Alkylating Agents , 1955 .